Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7192264 | 0.85 | HSD17B10 (0.48) | HSD17B10TSHRHTTRAB9ASMN1; SMN2 | |
| SCHEMBL6461137 | 0.80 | RAB9A (0.70) | HSD17B10TSHRHTTRAB9ASMN1; SMN2 | |
| SCHEMBL6451390 | 0.80 | ALDH1A1 (0.59) | HSD17B10TSHRHTTRAB9ASMN1; SMN2 | |
| SCHEMBL1250042 | 0.78 | ALDH1A1 (0.56) | HSD17B10TSHRHTTRAB9ASMN1; SMN2 | |
| SCHEMBL6452396 | 0.78 | NOTUM (0.54) | HSD17B10HTTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL6450847 | 0.78 | RAB9A (0.64) | HSD17B10TSHRRAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL11816106 | 0.78 | RAB9A (0.72) | HSD17B10TSHRRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6449133 | 0.76 | KDM4E (0.66) | HSD17B10TSHRRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL20533001 | 0.76 | EGFR (0.52) | HSD17B10TSHRHTTRAB9ASMN1; SMN2 | |
| SCHEMBL5338382 | 0.76 | NPC1 (0.66) | HSD17B10TSHRHTTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | HSD17B10 205/4885TSHR 4398/4885HTT 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.